How long can one live after taking anlotinib?

Generally, the survival time of patients after taking anlotinib varies depending on the type of cancer and individual differences, making it impossible to determine an exact duration. If there are concerns, it is recommended to seek medical advice in advance. The specific analysis is as follows:

For patients with non-small cell lung cancer, clinical trials have shown a median overall survival of up to 9.6 months, with some patients extending survival to 12 months or longer through standardized treatment. In third-line treatment for small cell lung cancer, the median overall survival is typically 7.3 months, while patients who respond well to treatment may survive beyond three years.

In patients with soft tissue sarcoma, the use of anlotinib increases median overall survival from 10.4 months to 12.1 months. For patients with gastrointestinal stromal tumors, median overall survival can reach 15.8 months. These data indicate that the extent of survival improvement with anlotinib varies across different tumor types, and final outcomes are also influenced by individual health status, cancer stage, and combination treatment regimens.

During treatment, patients must strictly follow medical instructions and undergo regular monitoring of blood pressure, kidney function, thyroid function, and other indicators. If severe bleeding, persistent hypertension, or worsening hand-foot skin reactions occur, physicians should be contacted immediately to adjust the dosage or suspend treatment.